Skip to main content
Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News FAQ
On This Report

Sequencing Market Size & Growth Forecast 2027–2036, By Segments (Workflow, Product & Services, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 13985| Published Date: Aug-2026| Format: PDF, Excel
Market Outlook

Market Size and Growth Outlook

Sequencing Market size was over USD 27.8 billion in 2026 and is likely to grow at a 20.9% CAGR between 2027 and 2036, exceeding USD 185.48 billion by 2036. The industry revenue for 2027 is assessed at USD 32.69 billion.

Base Year Value (2026)
USD 27.8 billion
CAGR (2027-2036)
20.9%
Forecast Year Value (2036)
USD 185.48 billion
Historical Data Period
2022-2026
Largest Region
North America
Forecast Period
2027-2036

Get more details on this report

Request Free Sample Report
Snapshot

Sequencing Market Intelligence Snapshot

Regional Market Dynamics

  • North America captured 52.36% of the market in 2026, supported by advanced laboratory infrastructure, strong genomics adoption, and high sequencing activity across research, biotechnology, and clinical applications.
  • Asia Pacific is forecast to grow at a 23.76% CAGR as investments in genomic capabilities, expanding laboratory networks, and broader research and healthcare adoption accelerate sequencing deployment.

Segment Momentum

  • Sequencing led the workflow segment with a 59.22% share in 2026 because it is the core operational stage that drives instrument utilization, reagent consumption, and sample throughput before downstream interpretation begins.
  • Services are expanding rapidly as organizations increasingly outsource specialized sequencing workflows and data-related tasks to improve flexibility, manage complexity, and access expertise without significant in-house investment.

Market Expansion Drivers

  • Expanding adoption of next-generation sequencing in oncology and precision medicine driving market growth.
  • Rising demand for personalized medicine and genetic testing accelerating clinical sequencing applications.
  • Growth of population-scale genomics and national sequencing initiatives expanding research and diagnostics ecosystem.

Leading Market Participants

  • Key companies in the sequencing market include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V (Netherlands), Oxford Nanopore Technologies plc (U.K.), BGI Genomics Co., Ltd. (China), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Eurofins Genomics GmbH (Germany), DNASTAR, Inc. (U.S.).

Forecast Snapshot

Global Market Forecast Snapshot

Market Outlook

  • 2026 Market Size: USD 27.8 billion
  • 2027 Estimated Market Size: USD 32.69 billion.
  • Projected Market Size: USD 185.48 billion by 2036
  • Growth Forecast: 20.9% CAGR (2027-2036)

Regional and Segment Outlook

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Sequencing (Workflow) | Consumables (Product & Services) | Academic Research (End-use)
  • Emerging Opportunity Segment: Data Analysis (Workflow) | Services (Product & Services) | Clinical Research (End-use)
Market Dynamics

Market Growth Drivers and Industry Trends

Expanding adoption of next-generation sequencing in oncology and precision medicine driving market growth

The broader use of next-generation sequencing in oncology and precision medicine is increasing demand for advanced genomic analysis across clinical applications. Sequencing market growth is supported by its ability to generate detailed genetic information that can assist healthcare professionals in understanding disease characteristics and informing more targeted treatment approaches.

Rising demand for personalized medicine and genetic testing accelerating clinical sequencing applications

The shift toward personalized healthcare is increasing the need for genetic information to support individualized clinical decision-making and testing. As personalized medicine expands, sequencing market demand is strengthened by greater integration of genomic analysis into clinical workflows, particularly where genetic insights are relevant to diagnosis and treatment selection.

Growth of population-scale genomics and national sequencing initiatives expanding research and diagnostics ecosystem

Population-scale genomics programs and national sequencing initiatives are expanding the use of sequencing beyond individual clinical applications into broader research and diagnostic activities. Sequencing market development is supported by these initiatives as they create larger genomic datasets, strengthen research infrastructure, and widen access to sequencing-based analytical capabilities.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Expanding adoption of next-generation sequencing in oncology and precision medicine driving market growth 2.60% High North America, Europe High Near Term
Rising demand for personalized medicine and genetic testing accelerating clinical sequencing applications 2.30% High North America, Asia Pacific High Near Term
Growth of population-scale genomics and national sequencing initiatives expanding research and diagnostics ecosystem 1.90% High Asia Pacific, North America Medium Mid Term
Custom Research

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
Regional Forecast

Regional Demand Dynamics

Sequencing Market
Largest Region
North America
52.36% Market Share in 2026

North America (Largest Region)

The sequencing market was led by North America, which accounted for a 52.36% share in 2026, owing to advanced genomics infrastructure, strong research capabilities, and widespread adoption of sequencing technologies across healthcare and life sciences applications. The region has a well-established ecosystem for precision medicine, molecular diagnostics, biomedical research, and pharmaceutical development, creating sustained demand for high-throughput and increasingly sophisticated sequencing solutions. Expanding use of genomic information in disease research and personalized healthcare, together with continued investment in laboratory infrastructure and bioinformatics capabilities, is strengthening the region's market position.

Asia Pacific (Fastest-Growing Region)

Asia Pacific is experiencing the fastest growth in the sequencing market as healthcare systems expand their genomic capabilities and research institutions increase investment in advanced molecular technologies. Growing interest in precision medicine, population genomics, disease surveillance, and biotechnology research is broadening the application base for sequencing. Improvements in laboratory infrastructure, availability of trained scientific professionals, and increasing integration of genomic testing into healthcare are supporting wider adoption. Public and private investment in biotechnology and research infrastructure is further improving the region's capacity to deploy sequencing technologies across clinical and research settings.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
Country Insights

Key Country Insights

Germany 🇩🇪

Research Infrastructure Strength

Germany prioritizes sequencing technologies across academic research, biotechnology, and clinical laboratories. Investment in standardized genomic workflows and advanced analytical platforms supports wider adoption in healthcare and life sciences.

France 🇫🇷

Translational Genomics Focus

France advances sequencing adoption by connecting genomic research with clinical practice in oncology and inherited disease testing. Healthcare institutions emphasize quality standards and collaborative research to enhance genomic medicine capabilities.

Italy 🇮🇹

Laboratory Modernization

Italy is modernizing sequencing laboratories with greater emphasis on molecular diagnostics, research collaboration, and workflow automation. Clinical institutions are expanding genomic testing capacity to support personalized treatment approaches across multiple specialties.

Japan 🇯🇵

Precision Healthcare Integration

Japan incorporates sequencing technologies into precision healthcare programs, rare disease research, and oncology diagnostics. Laboratories continue improving workflow efficiency while expanding genomic testing capabilities across clinical settings.

South Korea 🇰🇷

Biotechnology Innovation Hub

South Korea strengthens the sequencing market through biotechnology innovation, precision medicine initiatives, and expanding genomic research. Companies are investing in automation and data analysis solutions to improve laboratory productivity and clinical utility.

United States 🇺🇸

Clinical Genomics Expansion

The U.S. sequencing market continues advancing through clinical diagnostics, precision medicine, and pharmaceutical research initiatives. Healthcare providers and research organizations are increasing adoption of high-throughput platforms and bioinformatics capabilities for broader genomic applications.

Segment Analysis

Segment Leadership and Growth Trends

Sequencing Market Share (%), by Workflow, 2026

Sequencing
Pre-Sequencing
Data Analysis

Go beyond the chart, access full insights & data tables

Request Free Sample Report

Workflow Segment Analysis: Sequencing (Largest Segment) vs Data Analysis (Fastest-Growing Segment)

The sequencing segment led the sequencing market, holding the largest share of 59.22% in 2026, supported by its central role in generating genomic data across research, clinical diagnostics, drug development, and other life science applications. Continued demand for high-throughput sequencing workflows, broader adoption of next-generation sequencing, and the increasing use of genomic information in precision medicine sustain the segment's strong position. Sequencing also remains the foundational stage of the workflow, creating consistent demand as laboratories expand genomic testing and research capabilities.

Data analysis represents the fastest-growing segment, reflecting the increasing complexity and volume of information generated through modern sequencing platforms. Advanced bioinformatics tools are becoming increasingly important for converting raw sequencing outputs into clinically and scientifically actionable insights. Growing reliance on automated interpretation, data visualization, variant identification, and integrated computational workflows is strengthening demand for sophisticated analysis capabilities, particularly as sequencing expands across clinical and research settings.

Product & Services Segment Analysis: Consumables (Largest Segment) vs Services (Fastest-Growing Segment)

Consumables accounted for the largest share of the sequencing market at 47.17% in 2026, owing to their recurring requirement throughout sequencing workflows. Reagents, kits, flow cells, and other consumable components are essential for sample preparation, library construction, sequencing, and related laboratory procedures, creating sustained demand as sequencing activity expands. Increasing adoption of sequencing across research, diagnostics, and pharmaceutical applications further supports recurring consumption and reinforces the segment's established market position.

Services are emerging as the fastest-growing segment as organizations increasingly seek specialized sequencing capabilities without having to establish and maintain complete in-house infrastructure. Outsourced sequencing, data processing, interpretation, and related technical services can provide access to specialized expertise and advanced technologies while reducing operational complexity. Growing demand for flexible research support and the increasing sophistication of genomic workflows are encouraging laboratories and other end users to incorporate external services into their sequencing programs.

Segment Sub-Segment Largest Segment Fastest Growing
Workflow Pre-Sequencing, Sequencing, Data Analysis Sequencing Data Analysis
Product & Services Platform, Consumables, Services, Software Consumables Services
End-use Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Others Academic Research Clinical Research
Read our Research Approach →
Competitive Landscape

Competitive Landscape and Market Positioning

Key companies in the sequencing market:

1. Illumina Inc. (U.S.)

2. Thermo Fisher Scientific Inc. (U.S.)

3. F. Hoffmann-La Roche Ltd. (Switzerland)

4. QIAGEN N.V (Netherlands)

5. Oxford Nanopore Technologies plc (U.K.)

6. BGI Genomics Co. Ltd. (China)

7. Bio-Rad Laboratories Inc. (U.S.)

8. PerkinElmer Inc. (U.S.)

9. Eurofins Genomics GmbH (Germany)

10. DNASTAR Inc. (U.S.)

The sequencing market is advancing through rapid improvements in high-throughput analysis and cost-efficient genetic decoding methods. Continuous research efforts are expanding accuracy while reducing processing time. Integration of advanced computational tools is further strengthening data interpretation capabilities. The sequencing market is increasingly central to precision medicine and large-scale biological research initiatives.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
Illumina Inc. (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
QIAGEN N.V (Netherlands)
Oxford Nanopore Technologies plc (U.K.)
BGI Genomics Co. Ltd. (China)
Bio-Rad Laboratories Inc. (U.S.)
PerkinElmer Inc. (U.S.)
Eurofins Genomics GmbH (Germany)
DNASTAR Inc. (U.S.).
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
10x Genomics Aug-24 10x Genomics launched the Atera spatial genomics platform, featuring whole-transcriptome capabilities designed for high-resolution gene expression mapping. This expansion of the company's spatial biology portfolio enhances technical capabilities for oncology and translational research, providing advanced spatial sequencing tools to support deeper insights into complex biological systems and tumor microenvironments.
Illumina Aug-24 Illumina acquired SomaLogic for approximately $425 million, integrating proteomics capabilities into its core multiomics strategy. This strategic acquisition is intended to bridge genomic and proteomic data analysis, allowing for more comprehensive biological insights and strengthening Illumina’s competitive positioning in the precision diagnostics and life science research tool markets.
Oxford Nanopore Technologies Aug-24 Oxford Nanopore Technologies entered a partnership with Lonza to develop a GMP-focused mRNA quality control solution. By integrating sequencing-based analysis into biopharmaceutical manufacturing workflows, the collaboration aims to standardize and accelerate regulatory-grade testing, providing a scalable solution for mRNA therapeutic quality assurance.
Roche Jul-24 Roche is advancing its sequencing-by-expansion (SBX) technology through strategic collaborations, including efforts with the Broad Institute. The development program focuses on clinical validation for high-accuracy applications like newborn screening, positioning Roche to challenge existing next-generation sequencing standards with a technology platform designed for clinical speed and diagnostic precision.
Illumina Jul-24 Illumina partnered with NVIDIA to integrate the DRAGEN bioinformatics software into accelerated computing platforms via Illumina Connected Analytics. This collaboration enhances genomic data processing speeds, providing the computational scalability required for AI-enabled sequencing analytics in large-scale precision medicine and complex research environments.
Avance Biosciences Jul-24 Avance Biosciences established a Next-Generation Sequencing Center of Excellence in Houston to expand its contract research infrastructure. The facility is equipped to provide advanced genomic analysis and translational research services, supporting biopharmaceutical R&D efforts with high-capacity sequencing and molecular biology capabilities.
Baylor Genetics Jun-24 Baylor Genetics and Baylor College of Medicine inaugurated a Medical Genetics Multi-Omics Laboratory to centralize integrated genetic testing. The facility utilizes a multi-omic approach, combining advanced sequencing with molecular diagnostics to improve diagnostic yield for rare diseases and accelerate research in precision medicine.
Illumina May-24 Illumina commercially launched the NovaSeq X Plus, a high-throughput sequencing platform engineered to improve speed, scalability, and cost efficiency. By significantly increasing data output capacities, the system supports large-scale clinical and research sequencing initiatives, reinforcing the company's infrastructure leadership within the next-generation sequencing market.
Ultima Genomics May-24 Ultima Genomics initiated the rollout of an ultra-high-throughput sequencing system designed for automated, continuous operation. The platform features flexible run configurations aimed at increasing throughput and reducing costs for germline and large-scale research applications, strengthening the company’s competitive footprint in the high-capacity genome sequencing segment.
Illumina Mar-23 Illumina launched its Complete Long Read technology, enabling the generation of both long and short reads on a single sequencing instrument. This technological innovation addresses critical needs for improved genomic assembly and variant detection, marking a significant advancement in the flexibility and diagnostic utility of NGS workflows.
Report Customization

Customize Your Report

Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.

1 Custom Segments 2 Custom TOC 3 Related Reports

Sequencing Market — Custom Segments

Segment Sub-Segment
Sequencing Technology Sanger Sequencing, Short-Read Next-Generation Sequencing, Long-Read Sequencing, Single-Cell Sequencing
Sample Type DNA, RNA, Whole Genome, Targeted Panels, Single-Cell Samples
Deployment Model In-House Sequencing, Core Facility-Based Sequencing, Contract Sequencing Services, Cloud-Enabled Sequencing

Sequencing Market — Custom TOC

Custom Chapter Custom Details
Precision Medicine Adoption Strategy
  • Precision Medicine Implementation Trends
  • Clinical Integration Across Disease Areas
  • Healthcare System Readiness
  • Investment and Adoption Priorities
  • Long-Term Growth Opportunities
Data Infrastructure and Bioinformatics Ecosystem
  • Genomic Data Management Landscape
  • Bioinformatics Platform Evolution
  • Cloud and High-Performance Computing Integration
  • Data Interoperability and Collaboration Models
  • Future Infrastructure Requirements
Sequencing Service Model Evolution
  • Laboratory and Service Delivery Models
  • Outsourcing and Partnership Trends
  • Commercialization Strategies
  • Customer Engagement and Value Creation

Need a different cut of the data?

Request Custom Research
Frequently Asked Questions

What is the current size of the sequencing market?

As of 2027 the market size of sequencing is valued at USD 32.69 billion.

What is the projected value of the sequencing industry by 2036?

Sequencing Market size was over USD 27.8 billion in 2026 and is likely to grow at a 20.9% CAGR between 2027 and 2036, exceeding USD 185.48 billion by 2036.

How is oncology-driven precision medicine reshaping purchasing priorities in the sequencing market?

Oncology-driven precision medicine is shifting purchasing toward high-throughput sequencing instruments, targeted oncology panels, bioinformatics pipelines, and interpretation services. As genomic profiling becomes routine in cancer care, procurement increasingly prioritizes integrated workflows that support clinical decision-making rather than isolated testing.

Why are national and population-scale genomics initiatives becoming a key growth engine for the sequencing market?

Population-scale genomics initiatives are building long-term sequencing infrastructure, standardizing genomic data practices, and expanding institutional expertise. This creates an ecosystem effect that lowers adoption barriers for hospitals and research centers while broadening sequencing use across clinical and translational applications.

Why is Sequencing the largest workflow segment in the sequencing market?

Sequencing led the workflow segment with a 59.22% share in 2026 because it is the core operational stage that drives instrument utilization, reagent consumption, and sample throughput before downstream interpretation begins.

Why are Services the fastest-growing product and services segment in the sequencing market?

Services are expanding rapidly as organizations increasingly outsource specialized sequencing workflows and data-related tasks to improve flexibility, manage complexity, and access expertise without significant in-house investment.

What makes North America the leading region in the sequencing market?

North America captured 52.36% of the market in 2026, supported by advanced laboratory infrastructure, strong genomics adoption, and high sequencing activity across research, biotechnology, and clinical applications.

Why is Asia Pacific the fastest-growing sequencing market?

Asia Pacific is forecast to grow at a 23.76% CAGR as investments in genomic capabilities, expanding laboratory networks, and broader research and healthcare adoption accelerate sequencing deployment.

Who are the leading players in the sequencing landscape?

Key companies in the sequencing market include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V (Netherlands), Oxford Nanopore Technologies plc (U.K.), BGI Genomics Co., Ltd. (China), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Eurofins Genomics GmbH (Germany), DNASTAR, Inc. (U.S.).
Testimonials

Our Clients

"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."

Project Manager
Siemens Healthcare

"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."

Research and Development (R&D) Manager
GC Biopharma

"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."

Quality Assurance Manager
Medtronic
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →